Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW, Chairman & CEO

Serial biotech experience as CEO, CFO, Chair, Exec Chair

Merck, GSK, Pharmacia, J+J

Launched 5 blockbusters during career, including antivirals

Dale Chappell, MD, MBA, Chief Scientific Officer

Founder, Black Horse Capital Advisors

Decades of biotechnology investment experience

HHMI Fellow, National Cancer Institute, Rosenberg Lab

Multiple publications in T-cell therapy, GM-CSF and immunology pathways

Edward P. Jordan, MBA, Chief Commercial Officer

Over 20 years experience building and leading commercial organizations

Broad commercial experience spanning many therapeutic areas

Biotech builder with biologic experience

Extensive launch experience and builder of new therapeutic markets

DBV Technologies, AMAG, TEVA, Schering-Plough

Bob Atwill, MBA, SVP, Head of Asia-Pacific Region and Business Development

Over 30 years of executive pharma, biotech, cell therapy and healthcare experience

Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years

Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy

GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma

APAC based cross-border M&A and capital service principal with Eaton Square